

Fig. 1C





Fig. 2A






Fig. 2D







Fig. 3










Fig. 5B







Fig. 5C








Fig. 6B












Fig. 7C




Fig. 8A




Fig. 8B








Fig. 9














Fig. 12



Fig. 13

dArgo-2 immunoblot






Fig. 14






Fig. 15






Fig. 16







Fig. 17








Fig. 19




Fig. 20B







Fig. 21










Fig. 23



QPHQQQQQSSRQQPSTSSGGSRASGFQQGGQQQKSQDAEGWTAQKKQGKQQVQGWTKQ GOQGGHQQGRQGQDGGYQQRPPGQQQGGHQQGRQGQEGGYQQRPPGQQQGGHQQGRQG QEGGYQQRPSGQQQGGHQQGRQGQEGGYQQRPPGQQQGGHQQGRQGQEGGYQQRPSGQ QQGGHQQGRQGQEGGYQQRPSGQQQGGHQQGRQGQEGGYQQRPSGQQQGGHQQGRQGQ EGGYQQRPPGQQPNQTQSQGQYQSRGPPQQQQAAPLPLPPQPAGSIKRGTIGKPGQVG INYLDLDLSKMPSVAYHYDVKIMPERPKKFYRQAFEQFRVDQLGGAVLAYDGKASCYS VDKLPLNSQNPEVTVTDRNGRTLRYTIEIK**ETGDSTIDLK**SLTTYMNDR**IFDKPMR**AM QCVEVVLASPCHNKAIRVGR**SFFK**MSDPNNRHELDDGYEALVGLYQAFMLGDRPFLNV DISHKSFPISMPMIEYLERFSLKAK**INNTTNLDYSR**RFLEPFLRGINVVYTPPQSFQS APRVYRVNGLSR**APASSETFEHDGK**KVTIASYFHSRNYPLKFPQLHCLNVGSSIKSIL LPIELCSIEEGQALNRKDGATQVANMIKYAATSTNVRKRKIMNLLQYFQHNLDPTISR FGIRIANDFIVVSTRVLSPPQVEYHSKRFTMVKNGSWRMDGMK**FLEPKPK**AHKCAVLY CDPRSGRKMNYTQLNDFGNLIISQGKAVNISLDSDVTYRPFTDDERSLDTIFADLKRS QHDLAIVIIPQFRISYDTIKQKAELQHGILTQCIKQFTVERKCNNQTIGNILLKINSK LNGINHKIKDDPRLPMMKNTMYIGADVTHPSPDQREIPSVVGVAASHDPYGASYNMQY RLQRGALEEIEDMFSITLEHLRVYKEYRNAYPDHIIYYRDGVSDGQFPKIKNEELRCI KQACDKVGCKPKICCVIVVKRHHTRFFPSGDVTTSNKFNNVDPGTVVDRTIVHPNEMQ FFMVSHQAIQGTAKPTRYNVIENTGNLDIDLLQQLTYNLCHMFPRCNRSVSYPAPAYL AHLVAARGR**VYLTGTNR**FLDLKKEYAKRTIVPEFMKKNPMYFV

Fig. 24






Fig. 25







Fig. 26


**EGFP** 


EGFP



Production of dsRNA homologous to target mRNA


Stable suppression of transgene expression in ammalian cells Figure 28









#### Figure 30 RNAi in ES cells







# Figure 31 RNAi in mouse embyronic cells (P19)













P19 GFP hairpin clone number #10 48hrs post-transfection Fluorescent microscopy superimposed with bright field


Figure 34 Silencing is specific and requires dsRNA














In vitro synthesis of siRNAs by T7 RNA polymerase <u>o</u> Figure 36

<del>ر</del>خ

transcribe/anneal



assay phenotype

Brings large-scale projects within reasonable budget range ~ \$16/siRNA versus ~\$400/siRNA for chemical synthesis DNA synthesis/RNA transcription



#### Figure 37

#### Luciferase siRNA

UCGAGGUACUCAGCGUAAGUG


### Luciferase Let-7 like


CAUCGACUGAAAUCCCUGCUUU GUAGCUGAUUUUAGGGACUAUUAGGUAAA UCCCG C


### Luciferase simple hairpin


CAUCGACUGAAAUCCCUGGUAAUCCGUUG U GUAGCUGACUUNAGGGACCAUUAGGGACCAUUAGGGACCAUUAGGCAAC A
















# Stable Suppression by short dsRNAs - stable expression strategies Figure 43

T7 ribozyme

T7 gives site-specific initiation. 3' end formation Achieved with ribozyme (e.g. hepatitis delta virus ribozyme).

polIII terminator

polIII gives site-specific initiation.

Example promoters – U6 snRNA, H1 RNA, SRP RNAs (7SL)

3' end formation

Achieved with native terminator (e.g. TTTTT). Leaves the last TT, so that could be used to pair to transcript.


Could also use VA1, tRNA etc but would have to couple with Ribozyme since those promoters need also internal elements.

politi


polII gives site-specific initiation. Example promoters Would be UI snRNA promoters, CMV etc...

3' end formationachieved with ribozyme (e.g. hepatitis delta virus ribozyme).





Automatic subcloning into vector of choice




Stable suppression by expressed RNAi



Figure 46







#### Figure 47

## Mouse Tyrosinase Promoter

